The scaleup developed a platform for providing children, teenagers and young adults with psychological support
Handspring, an US virtual platform offering mental health support services for children, adolescents and young adults, secured a series B round of 19 million US Dollars that Angelini Ventures, the corporate venture capital of the eponymous Italian pharmaceutical company, joined as new investor.
RPS Ventures acted as lead investor, while Cobalt Ventures, NextView Ventures, nvp capital, Hyde Park Angels, and Cornucopian Capital renewed their support to the firm (press release).
After such a round, Handspring raised a total of 37 million since its launch and consolidated the credibility of the clinical model and the ability to expand the range of services on offer.
Such a deal is part of the strategy of Angelini Ventures ceo Paolo Di Giorgio who aims to support companies capable of innovating care models and improving access to and the quality of services while implementing an Impact Investing strategy, as Clinical Director Fabrizio Calisti said to BeBeez Magazine.
Angelini Ventures invested in mental health platform Serenis in November 2022 (see here a previous post by BeBeez) and in September 2025 (see here a previous post by BeBeez). In such a rapidly expanding therapeutic area there are needs that remain largely unmet. The focus is on solutions that enable early diagnosis, continuity of care and personalised treatment pathways, with a measurable impact on patients and healthcare systems.
Handspring operates in eight States and will invest the raised proceeds in its domestic growth, strengthening the clinical team, developing treatment programmes and advancing the proprietary technology platform.
Nancy Hilliker (RPS Ventures) and Dipa Mehta (Cobalt Ventures) will join the Handspring board while Sarah Fox (Angelini Ventures) will act as observer.
Tanja Dowe, a managing director of Angelini Ventures, said: “The investment in Handspring confirms our commitment to supporting innovative care models in an area of increasing priority such as the mental health of children and adolescents, where we see significant opportunities for growth. Handspring stands out for its clinically rigorous approach, focused on the quality of outcomes and the continuity of the therapeutic journey, and for a model based on professionals who are employed and trained to treat even the most complex cases: these are fundamental elements for creating sustainable solutions and effective programmes, tailored to the individual.” Fox added: “Paediatric mental health is one of the healthcare sector’s greatest unmet needs. Handspring has taken a differentiated approach through its innovative therapeutic model, insurance partnerships, family-centred care and proprietary artificial intelligence-based technology. We are delighted to support the team in expanding access to evidence-based care and improving outcomes for children and families.”
Handspring uses an integrated platform that facilitates telemedicine, automated clinical transcription and the matching of families with therapists. The clinical model invests in professionals with a direct hiring of therapists that receive in-house training in evidence-based methodologies and ongoing supervision.
Since 2021, Handspring supported over 4,000 families and has increased its revenue tenfold over the last two years.
Clinical results show that 93% of families report an improvement in their daily lives, whilst 81% of patients treated for anxiety and 78% of those treated for depression have made progress as measured by validated scales.
Angelini Ventures previously invested in the US and abroad. In 2025, the fund joined Neva (Intesa Sanpaolo Group) which led a Series B 84 million euros funding round for German Nuclidium, a clinical-stage radiopharmaceutical firm developing a platform that uses copper isotopes (Cu-61 and Cu-67) for applications in oncology (see here a previous post by BeBeez). In June 2025, Angelini Ventures joined a 11.25 million euros round of Elkedonia, a Franco-Belgian biotechnology company that is developing an innovative neuroplastogen for the treatment of treatment-resistant depression and other neuropsychiatric disorders which also attracted the resources of lead investors WE Life Sciences and Kurma Partners (see here a previous post by BeBeezand another previous post of BeBeez).
In November 2023, Angelini Ventures poured 3 million euros in Nextsense, a developer of innovative technologies in the field of infection control (see here a previous post by BeBeez).
In June 2026, Angelini Ventures and other investors fetched 340 million US Dollars out of the sale of their stakes in US Noctrix Health to ResMed, an Australian producer of medical devices for respiratory and sleep-related disorders (see here a previous post by BeBeez).
BeBeez Private Data, the private capital database of BeBeez and FSI, monitors Angelini Ventures and its investments. Find out here how to subscribe for one month or one year or Click here for booking a demo videocall with BeBeez database manager
